myTomorrows ads

Having worked close to a decade in Expanded Access (Jan 2027 will be my 10 year anniversary at myTomorrows 🎉), it has shown me that access pathways rarely stand still. 🌍 Right now, global pricing pressure is changing who gets access, and when. With MFN dynamics and international reference pricing, launch in some markets may be delayed for years after approval. Expanded Access has long been the route for patients with no other options. But free-of-charge programs are not sustainable to run forever. In the right markets, for the patients who need it, and where regulations allow, chargeable Expanded Access may offer a sustainable pathway for patients and sponsors alike. On Thursday, Nov 19, I’m joining Mallory Fredericks to host a live webinar for BioPharma professionals: 💡How pricing pressure and staggered launches are widening the access gap 💡When chargeable expanded access may offer a sustainable pathway 💡The regulatory, reimbursement and operational factors that decide feasibility, market by market 🗓️ Thursday, Nov 19 | 5:00 pm CET / 11:00 am ET / 8:00 am PT Register here ⬇️ https://lnkd.in/epJmfXWF Can’t make it live? Register anyway and we’ll send you the recording. #expandedaccess #patientaccess #marketaccess #biopharma #mytomorrows

A treatment can be approved in one country and still be unavailable in the next. For patients with no other options, that difference matters. Staggered launches aren’t new, but the gap between countries is getting wider as global pricing pressure reshapes launch sequencing. Where regulations allow, chargeable expanded access may offer a way for sponsors to help close this gap, but the rules vary widely by country. Regulatory frameworks, reimbursement factors, operational setup, and stakeholder expectations all shape whether a chargeable program is feasible, and whether it offers a sustainable pathway for both patients and sponsors. On Nov 19, Karlijn Doorn, PhD and I will host a webinar for BioPharma professionals where we’ll unpack how to approach this in practice. We’ll cover: ✅ Where the access gap is widening, and why ✅ When chargeable expanded access can be a sustainable option, before launch or where commercialization is delayed ✅ What factors to consider when moving from global access strategy to local execution 🗓️ Thursday, Nov 19 | 5:00 pm CET / 11:00 am ET / 8:00 am PT Save your spot: https://lnkd.in/eM53_nGZ Can’t make it live? Register anyway and we’ll send you the recording. #expandedaccess #marketaccess #launchstrategy #biopharma #mytomorrows

When launches are delayed or unfeasible, when do patients get access? Join our Nov 19 webinar on the strategic role of chargeable expanded access.

Pricing and reimbursement hurdles can delay access for years after approval. Join our Nov 19 webinar on where chargeable expanded access may fit.

Discover how evolving ethical guidance and real-world strategies are shaping patient-centered solutions to address access gaps for patients following clinical trial completion.

Pricing pressure is changing who gets access, and when. On Nov 19, we discuss when chargeable expanded access may offer a sustainable pathway.